PHIBRO ANIMAL HEALTH CORP (PAHC) FY2025 10-K Annual Report
PHIBRO ANIMAL HEALTH CORP (PAHC) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Aug 27, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
PHIBRO ANIMAL HEALTH CORP FY2025 10-K Analysis
Business Overview
- • Core business model: Global animal health and mineral nutrition solutions for livestock and companion animals, marketing ~800 product lines across 90 countries
- • New acquisition: Zoetis medicated feed additive portfolio acquired for $297.5M, adding $208.2M net sales in FY25 and 6 manufacturing sites in US, Italy, China
Management Discussion & Analysis
- • Revenue $1.296B, up 27% YoY from $1.018B; Animal Health best segment $963M, up 36% YoY; Performance Products worst $80.2M, up 19%
- • Adjusted net income $84.9M, up 76% YoY from $48.4M; adjusted diluted EPS $2.09 vs $1.19 prior year
Risk Factors
- • Cybersecurity attacks increasing in sophistication, with potential for material business impact
- • AI technology adoption risks, including compliance with privacy regulations and ethical use across enterprise
PHIBRO ANIMAL HEALTH CORP FY2025 Key Financial MetricsXBRL
Revenue
$1.3B
▲ +27.4% YoY
Net Income
$48M
▲ +1897.7% YoY
Gross Margin
30.9%
▲ +9bp YoY
Operating Margin
8.5%
▲ +328bp YoY
Net Margin
3.7%
▲ +349bp YoY
ROE
16.9%
▲ +1595bp YoY
Total Assets
$1.4B
▲ +38.6% YoY
EPS (Diluted)
$1.19
▲ +1883.3% YoY
Operating Cash Flow
$80M
▼ -8.5% YoY
Source: XBRL data from PHIBRO ANIMAL HEALTH CORP FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on PHIBRO ANIMAL HEALTH CORP
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.